Lucigen announced recently it was awarded an SBIR Phase II grant to continue work on a DNA cloning vector for the growing protein expression market.

According to a release, Lucigen Senior Scientist Dr. Ron Godiska will be leading the research on DNA cloning, which could be used for human diseases.

In addition, Lucigen announced it can now expand from the bacterial protein expression market into other disease-relevant areas.